CASE REPORT article
Front. Immunol.
Sec. Inflammation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1574255
This article is part of the Research TopicPrecision Medicine in Immunology: Targeting Inflammation to Improve Patient Care with Immune DiseasesView all 3 articles
Case Report: First Successful Treatment of Epidermolytic Ichthyosis with Vunakizumab
Provisionally accepted
Wenjie Cheng1,2,3
Chaolan Pan1,2,3XiaoXiao Wang1,2,3
Zhe Sun1,2,3
Pei-Yi Sun1,2,3Jiawen Li1,2,3zhirong yao1,2,3
Jia Zhang1,2,3*- 1Dermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- 2Department of Dermatology, Shanghai Jiaotong University School of Medicine, Shanghai, China
- 3Institute of Dermatology, Shanghai Jiaotong University School of Medicine, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Ichthyoses, a group of skin cornification disorders caused by protein and lipid abnormalities that disrupt epidermal functions, are mainly characterized by generalized scaling. This study is the first to report the use of Vunakizumab, China's first self-developed anti-IL-17A monoclonal antibody, in treating ichthyosis. We presented a case of a 4-year-old boy with epidermolytic ichthyosis (EI) due to a KRT1 gene mutation. Since birth, he has presented with generalized erythema, desquamation, and blister formation at the extremities. Then, palmoplantar hyperkeratosis gradually emerged, accompanied by severe pruritus. After a three-month treatment with Vunakizumab, symptoms alleviated significantly and inflammatory factor levels normalized. This not only shows the great potential of Vunakizumab in treating ichthyosis but also paves the way for further research on anti-IL-17A therapies for skin cornification disorders, offering treatment options for ichthyosis patients.
Keywords: Ichthyosis, Vunakizumab, Immunotherapy, KRT1 Gene Mutation, Epidermal Barrier Ichthyosis, Epidermal barrier dysfunction
Received: 10 Feb 2025; Accepted: 28 Apr 2025.
Copyright: © 2025 Cheng, Pan, Wang, Sun, Sun, Li, yao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jia Zhang, Dermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.